Core Viewpoint - ACM Research, Inc. is experiencing a positive stock performance, with a recent closing price of $26.51, reflecting a 1.77% increase from the previous day, outperforming major indices like the S&P 500, Dow, and Nasdaq [1] Financial Performance - The upcoming earnings report for ACM Research, Inc. is projected to show earnings of $0.42 per share, representing a year-over-year decline of 23.64% [2] - Revenue is expected to be $221.04 million, indicating a 9.17% growth compared to the same quarter last year [2] - For the annual period, earnings are anticipated to be $2 per share, with revenue projected at $912.29 million, reflecting shifts of -11.5% and +16.64% respectively from the previous year [3] Analyst Estimates - Recent changes in analyst estimates for ACM Research, Inc. indicate evolving short-term business trends, with upward revisions suggesting analysts' positive outlook on the company's operations and profit generation [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns ACM Research, Inc. a rank of 4 (Sell) [6] Valuation Metrics - ACM Research, Inc. is trading at a Forward P/E ratio of 13.02, which aligns with the industry average [7] - The Semiconductor Equipment - Material Services industry, to which ACM Research belongs, ranks in the bottom 5% of all industries, with a current Zacks Industry Rank of 236 [7][8]

Company Performance - Constellation Energy Corporation (CEG) closed at $320.66, marking a +1.73% move from the previous day, outperforming the S&P 500's gain of 1.11% [1] - Over the past month, shares of CEG gained 5.96%, surpassing the Oils-Energy sector's gain of 5.39% and the S&P 500's gain of 3.92% [1] Upcoming Earnings - The company is expected to report EPS of $2.06, reflecting a 22.62% increase from the prior-year quarter [2] - Revenue is anticipated to be $5.2 billion, indicating a 4.97% decline compared to the year-ago quarter [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $9.45 per share, with revenue expected to reach $23.78 billion, representing changes of +9% and +0.9% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for CEG suggest a positive outlook on business operations and profit generation [4] - The Zacks Consensus EPS estimate has shifted 0.03% upward over the past month, and CEG currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - CEG has a Forward P/E ratio of 33.35, which is a premium compared to the industry average Forward P/E of 19.43 [7] - The company also has a PEG ratio of 2.47, compared to the Alternative Energy - Other industry's average PEG ratio of 2.19 [8] Industry Context - The Alternative Energy - Other industry, part of the Oils-Energy sector, ranks in the bottom 36% of all industries, with a Zacks Industry Rank of 159 [9]

Group 1: Stock Performance - Symbotic Inc. closed at $32.87, reflecting a decrease of -3.32% from the previous day, underperforming the S&P 500 which gained 0.96% [1] - Over the past month, shares of Symbotic Inc. have appreciated by 18.24%, outperforming the Business Services sector's decline of 5.01% and the S&P 500's increase of 0.5% [1] Group 2: Financial Expectations - Analysts expect Symbotic Inc. to report earnings of $0.03 per share, indicating a year-over-year growth of 250% [2] - The consensus estimate projects revenue of $536.41 million, reflecting a 9.06% increase from the same quarter last year [2] - For the full year, earnings are projected at $0.20 per share and revenue at $2.22 billion, representing changes of +350% and +19.32% respectively from the prior year [3] Group 3: Analyst Estimates and Ratings - Recent changes to analyst estimates for Symbotic Inc. indicate positive sentiment towards the company's business operations and profit generation capabilities [4] - The Zacks Rank system, which assesses estimate changes, currently rates Symbotic Inc. at 5 (Strong Sell), indicating a stagnant consensus EPS estimate over the past month [6] Group 4: Valuation Metrics - Symbotic Inc. has a Forward P/E ratio of 168.6, significantly higher than the industry average Forward P/E of 19.97 [7] - The company has a PEG ratio of 5.62, compared to the industry average PEG ratio of 1.47 [7] Group 5: Industry Context - The Technology Services industry, part of the Business Services sector, holds a Zacks Industry Rank of 48, placing it in the top 20% of over 250 industries [8] - Research indicates that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [8]

Company Performance - Amgen's stock price ended at $272.44, reflecting a -5.84% change from the previous day's closing price, underperforming the S&P 500's daily gain of 0.96% [1] - Prior to the recent trading session, Amgen's shares had increased by 6.5%, outperforming the Medical sector's decline of 0.85% and the S&P 500's gain of 0.5% [1] Financial Projections - Amgen's upcoming earnings per share (EPS) are projected to be $5.21, indicating a 4.83% increase from the same quarter last year, with revenue expected to reach $8.86 billion, a 5.59% increase compared to the year-ago quarter [2] - For the full year, the Zacks Consensus Estimates project earnings of $20.82 per share and revenue of $35.22 billion, reflecting changes of +4.94% and +5.36% respectively from the previous year [3] Analyst Estimates and Rankings - Recent adjustments to analyst estimates for Amgen are crucial as they indicate changing near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3][4] - The Zacks Rank system, which evaluates estimate changes, currently ranks Amgen at 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.16% in the past month [5] Valuation Metrics - Amgen has a Forward P/E ratio of 13.9, which is lower than the industry average of 19.6, suggesting that Amgen is trading at a discount compared to its peers [6] - The company has a PEG ratio of 2.62, while the average PEG ratio for Medical - Biomedical and Genetics stocks is 1.36, indicating a higher valuation relative to expected growth [7] Industry Context - The Medical - Biomedical and Genetics industry, which includes Amgen, holds a Zacks Industry Rank of 89, placing it in the top 37% of over 250 industries, suggesting a favorable performance outlook [8]

Company Performance - Canopy Growth Corporation (CGC) closed at $1.19, down 4.03% from the previous trading session, underperforming the S&P 500's gain of 0.96% [1] - The stock has decreased by 32.24% over the past month, contrasting with the Medical sector's loss of 0.85% and the S&P 500's gain of 0.5% [1] Earnings Projections - The upcoming earnings report is projected to show an earnings per share (EPS) of -$0.1, which represents a 72.97% increase from the same quarter last year [2] - Revenue is anticipated to be $48.08 million, indicating a 0.64% decrease from the same quarter last year [2] Full Year Estimates - For the full year, earnings are projected at -$0.41 per share and revenue at $199.33 million, reflecting changes of +86.24% and +3.12% respectively from the previous year [3] - Recent analyst estimate revisions suggest a positive outlook for the company's business and profitability [3] Analyst Ratings - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently rates Canopy Growth Corporation at 3 (Hold) [5] - The consensus EPS projection has increased by 22.27% in the past 30 days, indicating some analyst optimism [5] Industry Context - The Medical - Products industry, part of the Medical sector, holds a Zacks Industry Rank of 164, placing it in the bottom 34% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [6]

In the latest close session, Sterling Infrastructure (STRL) was up +2.08% at $222.50. The stock outperformed the S&P 500, which registered a daily gain of 0.96%. Meanwhile, the Dow experienced a rise of 0.89%, and the technology-dominated Nasdaq saw an increase of 0.94%. Coming into today, shares of the civil construction company had gained 18.2% in the past month. In that same time, the Construction sector lost 2.29%, while the S&P 500 gained 0.5%. Market participants will be closely following the financia ...

In the latest trading session, Powell Industries (POWL) closed at $180.52, marking a +2.91% move from the previous day. This move outpaced the S&P 500's daily gain of 0.96%. Elsewhere, the Dow gained 0.89%, while the tech-heavy Nasdaq added 0.94%. The energy equipment company's stock has climbed by 0.41% in the past month, falling short of the Industrial Products sector's gain of 2.02% and the S&P 500's gain of 0.5%.The upcoming earnings release of Powell Industries will be of great interest to investors. O ...

Company Performance - Superior Group (SGC) shares decreased by 2.5% to $9.74, underperforming the S&P 500's loss of 0.22% on the same day [1] - Over the past month, SGC shares appreciated by 1.32%, outperforming the Consumer Discretionary sector's loss of 0.1% and the S&P 500's gain of 0.45% [1] Upcoming Earnings - Analysts expect Superior Group to report earnings of $0.07 per share, indicating a year-over-year growth of 75% [2] - The consensus estimate for quarterly revenue is $135.03 million, reflecting a 2.5% increase from the previous year [2] Full-Year Estimates - Zacks Consensus Estimates project full-year earnings of $0.49 per share and revenue of $559.79 million, representing year-over-year declines of 32.88% and 1.04%, respectively [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for Superior Group are important as they reflect short-term business trends [4] - Positive estimate revisions are viewed as a sign of optimism regarding the business outlook [4] Zacks Rank and Performance - The Zacks Rank system currently rates Superior Group as 4 (Sell), with the consensus EPS estimate decreasing by 13.6% over the past month [6] - Historically, 1 ranked stocks in the Zacks Rank system have yielded an average annual return of +25% since 1988 [6] Valuation Metrics - Superior Group has a Forward P/E ratio of 20.28, which is higher than the industry average Forward P/E of 13.65 [7] - The company's PEG ratio stands at 2.03, compared to the industry average PEG ratio of 1.98 [8] Industry Context - The Textile - Apparel industry, part of the Consumer Discretionary sector, holds a Zacks Industry Rank of 208, placing it in the bottom 16% of over 250 industries [9] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [9]

Core Viewpoint - Adma Biologics is experiencing a decline in stock performance, with a notable drop in the past month, while upcoming earnings are expected to show positive growth in EPS and revenue [1][2][3]. Company Performance - The stock price of Adma Biologics closed at $17.74, reflecting a decrease of 2.15% from the previous day, underperforming compared to the S&P 500's loss of 0.22 [1] - Over the past month, the stock has decreased by 10.07%, contrasting with the Medical sector's stability and the S&P 500's slight gain of 0.45% [1] Earnings Expectations - Analysts anticipate an EPS of $0.14 for the upcoming earnings report, representing a 7.69% increase year-over-year [2] - Revenue is expected to reach $121.1 million, indicating a 12.98% growth compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at $0.67 per share, reflecting a 36.73% increase from the previous year [3] - Revenue for the year is estimated at $505.8 million, which would be an 18.61% rise from the prior year [3] Analyst Estimates - Recent adjustments to analyst estimates for Adma Biologics are crucial, as they often indicate short-term business trends and analysts' confidence in the company's profitability [4] - Upward revisions in estimates suggest positive sentiment regarding the company's operational performance [4] Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining unchanged over the last 30 days [6] - The company is trading at a Forward P/E ratio of 27.26, which is higher than the industry average of 19.86 [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries [7] - The Zacks Industry Rank indicates that the top-rated industries tend to outperform the lower-rated ones by a factor of 2 to 1 [8]

Company Performance - Ardmore Shipping (ASC) closed at $10.13, reflecting a -3.89% change from the previous day, underperforming the S&P 500's daily loss of 0.22% [1] - The stock has increased by 9.91% over the past month, contrasting with the Transportation sector's decline of 2.83% and the S&P 500's gain of 0.45% [1] Earnings Projections - Ardmore Shipping is expected to report earnings of $0.24 per share, indicating a year-over-year decline of 78.76% [2] - Revenue is projected at $44.45 million, down 48.68% from the same quarter last year [2] Full Year Estimates - For the full year, earnings are projected at $1.17 per share and revenue at $180.69 million, representing declines of -58.8% and -33.85% respectively from the prior year [3] - Recent modifications to analyst estimates are crucial as they reflect near-term business trends, with positive revisions indicating optimism about the business outlook [3] Valuation Metrics - Ardmore Shipping has a Forward P/E ratio of 9.01, which is lower than the industry average Forward P/E of 9.62 [6] - The Transportation - Shipping industry currently holds a Zacks Industry Rank of 192, placing it in the bottom 22% of over 250 industries [6] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks delivering an average annual return of +25% since 1988 [5] - Ardmore Shipping currently holds a Zacks Rank of 3 (Hold), with no changes in the consensus EPS estimate over the last 30 days [5]